Researchers at the University of California San Diego School of Medicine are hopeful the combination of the experimental drug cirmtuzumab along with ibrutinub can halt the progression of chronic B-cell cancers. In an article published in the June 1 issue of Cell Stem Cell, researchers reported that treatment of 26 chronic leukemia patients with the experimental drug combination appeared to stop the disease’s progress.
Read More
0 Comments Click here to read/write comments
Tags: CA, University of California San Diego, San diego Biotech, Bioresearch product fair, San Diego, SDVS, UCSD, Research Funding, Biotechnology Vendor Showcase, laboratory equipment suppliers, cancer reserach, 2018, life sciecne, Blood Cancer, san diego research